C4 Therapeutics appoints Paige Mahaney as CSO effective Oct 28; Stewart Fisher retires

C4 Therapeutics, Inc.

Paige Mahaney, Ph.D., formerly SVP at Exelixis, appointed CSO effective October 28, 2024.
Stewart Fisher, Ph.D., retires as CSO Oct 28, will serve as Senior Scientific Advisor through Dec 2024, then consultant through Dec 2025.
Mahaney receives $510k base salary, $150k sign-on bonus, up to $75k relocation, and performance bonus up to 40% of base.
Mahaney granted inducement option for 345,600 shares (25% vests at 1 yr, rest over 3 yrs) and RSUs for 76,800 shares (vest over 4 yrs).
Fisher's retirement not due to any disagreement; consulting agreement provides continued equity vesting through Dec 2025.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Paige Mahaney

Chief Scientific Officer

CCCC · C4 Therapeutics, Inc.

Effective: 2024-10-28
Filed: October 16, 2024, 7:59 PM ET

On October 15, 2024, the Company announced the appointment of Paige Mahaney, Ph.D. as its Chief Scientific Officer, effective as of October 28, 2024.

Departed

Stewart Fisher

Chief Scientific Officer

CCCC · C4 Therapeutics, Inc.

Effective: 2024-10-28
Successor: Paige Mahaney
Filed: October 16, 2024, 7:59 PM ET

On October 11, 2024, Stewart Fisher, Ph.D. informed us of his intent to retire from the role of Chief Scientific Officer of C4 Therapeutics, Inc.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Paige Mahaney was appointed as Chief Scientific Officer at C4 Therapeutics, Inc..

Action: appointed
Role: Chief Scientific Officer

Exact text from the filing

On October 15, 2024, the Company announced the appointment of Paige Mahaney, Ph.D. as its Chief Scientific Officer, effective as of October 28, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Stewart Fisher retired as Chief Scientific Officer at C4 Therapeutics, Inc..

Action: retired
Role: Chief Scientific Officer

Exact text from the filing

On October 11, 2024, Stewart Fisher, Ph.D. informed us of his intent to retire from the role of Chief Scientific Officer of C4 Therapeutics, Inc.

View on SEC.gov

C4 Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-042879

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.